1 / 3

VII. Comparisons with Pancreastatin

VII. Comparisons with Pancreastatin. Porcine P ancreastatin. Unlike Pancreastatin The NETest i s NOT increased by p ancreas, kidney or liver damage. Comparisons of the NETest with CgA and Pancreastatin.

chastity-battle
Download Presentation

VII. Comparisons with Pancreastatin

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. VII. Comparisons with Pancreastatin Porcine Pancreastatin UnlikePancreastatin The NETest is NOTincreased by pancreas, kidney or liver damage

  2. Comparisons of the NETest with CgA and Pancreastatin NETest is a highly accurate biomarker (>90% metrics) and outperforms CgA and pancreastatin SENS = sensitivity, SPEC = specificity, PPV = Positive Predictive Value, NPV = Negative Predictive Value

  3. What constitutes a clinically effective circulating biomarker? An effective circulating biomarker must exhibit three key technical attributes: The marker must be present in peripheral body fluid It must be easy to detect or quantify in assays that are both affordable and robust Its appearance must be associated as specifically as possible with a specific tumor, preferably in a quantifiable manner. Measurement of a biomarker should be accurate, reliable, reproducible and differentiate between normal and the specific disease of interest. All performance metrics should be >80% Biomarkers on a roll. Nat Biotechnol.2010, 28431

More Related